Skip to content
Evigrade
MinorSelective serotonin reuptake inhibitors (SSRIs)×Systemic retinoid (vitamin A derivative)

Updated · Methodology

Mechanism

Several cytochrome P450 enzymes metabolise isotretinoin, with no single predominant one, and isotretinoin and its metabolites do not significantly change cytochrome P450 activity (Acnemin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, in vitro isotretinoin is metabolised mainly by CYP2C8, CYP2C9, CYP3A4 and CYP2B6 (isotretinoin capsules label, US Food and Drug Administration, FDA). Escitalopram inhibits CYP2D6 and weakly CYP2C19 (Cipralex SmPC, AEMPS), and in vitro it did not inhibit CYP3A4 or CYP2C9 (Lexapro label, FDA). The documents do not list CYP2D6 or CYP2C19, the enzymes escitalopram inhibits, among those that metabolise isotretinoin. Escitalopram itself is metabolised mainly by CYP2C19 and to a lesser extent by CYP3A4 and CYP2D6 (Cipralex SmPC, AEMPS).

Symptoms

The documents describe no symptoms linked to this combination. The isotretinoin SmPC reports depression, worsening of depression, anxiety, aggressive tendencies, mood changes and psychotic symptoms during treatment and, very rarely, suicidal ideation, suicide attempts and suicide (Acnemin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In studies, antidepressants increased the risk of suicidal behaviour compared with placebo in patients under 25. Depression itself raises the risk of suicidal thoughts (Cipralex SmPC, AEMPS).

Management

Isotretinoin can cause depression and worsening of depression and, very rarely, suicidal ideation and suicide attempts. Use it with particular caution in patients with a history of depression, monitor every patient for signs of depression and refer for appropriate treatment if needed (Acnemin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Before isotretinoin treatment, ask about any history of psychiatric disorder, and at each visit assess for depression, mood disturbance, psychotic symptoms or aggression. If these appear, stop isotretinoin at once (isotretinoin capsules label, US Food and Drug Administration, FDA). Stopping isotretinoin may not be enough to relieve the symptoms, and further psychiatric or psychological assessment may then be needed (Acnemin SmPC, AEMPS). According to the documents, the doses of escitalopram and isotretinoin need no change. No document names the pair, and the documents do not list CYP2D6 or CYP2C19, the enzymes escitalopram inhibits, among those that metabolise isotretinoin (Acnemin and Cipralex SmPCs, AEMPS; isotretinoin capsules and Lexapro labels, FDA). Monitor every patient taking an antidepressant for clinical worsening and suicidal thoughts, especially in the first months of treatment and after dose changes. Ask family members or caregivers to watch for changes in behaviour (Lexapro label, FDA). Monitor patients with a history of suicidal thoughts or attempts particularly carefully during treatment (Cipralex SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Escitalopram

Other interactions with Isotretinoin